...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Financials

On page 5 of MD&A it states all tranches were completed, the first three prior to July 31 the last one post July 31. The first three tranches are reflected in the current financials. 

Share
New Message
Please login to post a reply